Orange Book product · Brand (NDA)
ELLA
ULIPRISTAL ACETATE
At a glance
Aug 13, 2010
Approved
Brand (NDA)
Application
AB
TE code
8
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 13, 2010
16 yr 1 mo ago
Today
Patent 9844510 expires
Listed drug product patent expiration.
Dec 08, 2028
in 2 yr 6 mo
Patent 8735380 expires
Listed drug product patent expiration.
Feb 20, 2029
in 2 yr 9 mo
Patent 10159681 expires
Listed method-of-use patent (U-2510) expiration.
Apr 13, 2030
in 3 yr 10 mo
Patent 10772897 expires
Listed method-of-use patent (U-2958) expiration.
Apr 13, 2030
in 3 yr 10 mo
Patent 9283233 expires
Listed method-of-use patent (U-1821) expiration.
Apr 13, 2030
in 3 yr 10 mo
Patent 8512745 expires
Listed drug product patent expiration.
Jun 02, 2030
in 4 yr
Patent 8426392 expires
Listed method-of-use patent (U-1389) expiration.
Jun 12, 2030
in 4 yr
Patent 8962603 expires
Listed method-of-use patent (U-1657) expiration.
Jun 12, 2030
in 4 yr
Pharmaceutical detail
Active ingredient
ULIPRISTAL ACETATE
Strength
30MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 022474
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (8)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9844510 | Dec 08, 2028 | in 2 yr 6 mo | Product |
| 8735380 | Feb 20, 2029 | in 2 yr 9 mo | Product |
| 10159681 | Apr 13, 2030 | in 3 yr 10 mo | U-2510 |
| 10772897 | Apr 13, 2030 | in 3 yr 10 mo | U-2958 |
| 9283233 | Apr 13, 2030 | in 3 yr 10 mo | U-1821 |
| 8512745 | Jun 02, 2030 | in 4 yr | Product |
| 8426392 | Jun 12, 2030 | in 4 yr | U-1389 |
| 8962603 | Jun 12, 2030 | in 4 yr | U-1657 |
